Outstanding Results from EYLEA HD Clinical Trials
Recent data highlights a remarkable achievement in vision improvement and anatomical progress for patients utilizing EYLEA HD (aflibercept) Injection 8 mg. This development follows a three-year extension study of the Phase 3 PHOTON trial, demonstrating sustained benefits for individuals affected by diabetic macular edema.
Longer Dosing Intervals Provide Clinical Benefits
In the latest study results, a substantial 88% of EYLEA HD patients maintained a dosing interval of ?12 weeks at week 156, successfully preserving the visual enhancements and anatomical improvements achieved during the initial 96 weeks. Such findings underscore the efficacy of EYLEA HD, providing patients not only consistency in treatment but also a significant reduction in healthcare visits.
Reduced Fluid Reaccumulation
Patients transitioning to EYLEA HD reported a markedly slower rate of fluid reaccumulation compared to their prior treatment with EYLEA (aflibercept) Injection 2 mg. These results reinforce the notion of EYLEA HD having a longer duration of action, enabling patients to enjoy extended freedom from injections while maintaining their progress.
Safety Profile Remains Stable
Throughout this extensive study, the safety profile of EYLEA HD aligned with previously established data. Consistent findings indicate a tolerable safety margin similar to EYLEA. Noteworthy occurrences of ocular treatment emergent adverse events (TEAEs) were documented, including cataracts and vitreous floaters.
Impact on Diabetic Eye Disease Management
Diana V. Do, M.D., an ophthalmology professor and trial investigator, emphasized the significance of these findings. According to Dr. Do, many patients face the challenge of balancing treatment effectiveness with life obligations, such as work and family commitments. The outcomes from EYLEA HD not only validate its application as a first-line treatment but also offer hope for those battling diabetic eye diseases.
Trial Design and Patient Enrollment
Initially, participants in the PHOTON trial were randomly assigned into groups receiving either 12- or 16-week dosing intervals after three months of initial treatment. During the study, intervals were adjustable based on clinical response, allowing for tailored patient care. The vast majority of EYLEA HD patients who completed the study experienced sustained vision and anatomical improvements.
Collaborative Development with Bayer
EYLEA HD, also known as Eylea™ 8 mg in Europe and Japan, is co-developed by Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer AG. While Regeneron holds exclusive rights within the United States, Bayer enjoys the marketing rights internationally, with both companies sharing profits from EYLEA and EYLEA HD sales.
About Diabetic Eye Disease
Diabetic retinopathy (DR) is notable for causing microvascular damage in the retina, primarily stemming from impaired blood sugar regulation in diabetes patients. As the disease progresses, it can lead to severe conditions like proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME), significantly impacting vision. In the United States alone, around 1.5 million adults have been diagnosed with DME, while approximately 6 million experience DR without DME.
Regeneron’s Commitment to Eye Care Innovations
At Regeneron, innovation drives our endeavors as we develop groundbreaking therapies to improve eye health for countless individuals. EYLEA's advent revolutionized clinical practices within retinal disease treatment, emphasizing the importance of extensive research and patient care strategies. Our ongoing commitment remains steadfast in delivering effective treatments for conditions such as diabetic eye diseases.
Frequently Asked Questions
What is EYLEA HD?
EYLEA HD (aflibercept) Injection 8 mg is a treatment for diabetic macular edema, designed to provide long-lasting visual and anatomical benefits with fewer injections.
How long did the study on EYLEA HD last?
The extension study of the Phase 3 PHOTON trial lasted three years, with significant results reported at 156 weeks.
What were the primary outcomes of the trial?
The study revealed that patients sustained visual and anatomical improvements while achieving longer dosing intervals with EYLEA HD.
What is the safety profile of EYLEA HD?
The safety profile is consistent with EYLEA's established data, with no significant new safety concerns raised during the trial.
How is EYLEA HD administered?
EYLEA HD is administered as an injection into the eye, typically requiring three or four injections per year depending on patient response.
